focus -WSS

focus

author：entertainment 2025-09-30 00:36:17 - browse：6

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Susan Tousi leaves Illumina to head cancer liquid biopsy startup

hotspot

WSS

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Medicare has a new plan to address drug shortages

Listen: Wegovy in the brain & pivotal Alzheimer's data

Custom gene therapy hints at new path for rare disease treatments

Goldman Sachs launches $650M fund for life science investments

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

knowledge

focus

Wikipedia

Activists slam private health insurers over coverage restrictions

Videos point to link between seizures and unexplained toddler deaths

Hollywood unions extend contract negotiations for actors

U.K. sequencing study surfaces new findings about tumor DNA

Tori Bowie and the unacceptable rates of Black maternal death

How Medicaid coverage policies for immigrants impact new moms

George Santos makes 1st court appearance after pleading not guilty to 13 counts

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Alkermes shareholders re

UCB departs biotech trade group BIO

focus

Biden tests positive for Covid

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

WHO calls for emergency meeting on new China virus, as cases spread

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Feng Zhang, Grail founder join forces on new gene editing startup

Listen: Wegovy in the brain & pivotal Alzheimer's data

hotspot

hotspot

hotspot

focus